On February 10, 2026, the FDA publicly rejected Moderna's mRNA flu vaccine application, citing inadequate controlled studies. Eight days later, the agency reversed itself and agreed to a standard review. Moderna's stock soared. Public health experts winced. The reversal looked less like a regulatory correction and more like a negotiation with itself, conducted in public, with no explanation of what changed scientifically in those eight days. Nothing changed scientifically. That is the problem.
Regulatory uncertainty is not an abstract policy concern. It is a supply chain problem for the vaccines that end up in your insurer's formulary, and eventually in your arm. When manufacturers cannot predict whether an application will be approved, rejected, reversed, or subjected to testing standards that Villanova law professor Ana Santos Rutschman described in March 2026 as "impossible to achieve," they make rational business decisions: cut R&D investment, reduce headcount, and exit markets where the return on development is unpredictable. Moderna has already moved in this direction. The vaccine pipeline does not refill itself quickly.
The Departure That Tells You Everything
On March 6, Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, announced he will leave at the end of April after roughly a year in the role. His tenure included the Moderna reversal, denials of rare disease drugs that contradicted the administration's own deregulation posture, and a memo citing an unreleased FDA review linking COVID-19 vaccines to ten child fatalities, without providing the underlying data. That last point deserves emphasis: a top vaccine regulator circulated unsubstantiated safety claims that no one could verify. The scientific standard for that move is zero.
Some biotech investors read Prasad's exit as a stabilization signal. I understand the optimism. But regulatory credibility is not rebuilt by a personnel change. It is rebuilt by consistent, evidence-based decisions over time, and the institutional memory at FDA's biologics office is already scattered after years of political pressure and turnover under HHS Secretary Robert F. Kennedy Jr.
What Lands on Your Insurance Card
Your health plan's formulary for next flu season depends on vaccine manufacturers completing approval processes in time for production cycles. The accelerated approval pathway that FDA eventually extended to adults 65 and older for Moderna's vaccine carries an asterisk: post-approval studies are required, and the late invocation of that pathway is unusual enough that experts flagged it as disruptive to standard practice. Unusual regulatory maneuvers introduce timeline risk. Timeline risk means potential shortages. Shortages mean your insurer substitutes, rations, or excludes.
The fair point to grant here: scrutinizing vaccine approvals more rigorously is not automatically wrong. Accelerated pathways do sometimes outpace the evidence. But there is a difference between methodological rigor and an eight-day reversal driven by factors the agency never disclosed. One is science. The other is theater.
Congress should require the FDA to publish a written clinical rationale within 72 hours of any reversal of a prior approval decision. Not a press release. A document that a peer reviewer could evaluate. If the original rejection was scientifically justified, say so. If it was not, say that too. Drugmakers, insurers, and patients all make downstream decisions based on FDA signals. Those signals need to mean something consistent.
The February reversal meant Moderna could proceed. It did not mean the regulatory environment is predictable. Those are not the same thing, and the difference will show up in your 2027 premium.
